About Ribaxa+ 150mg Tablet
Ribaxa 150mg Tablet contains Olaparib, a targeted anticancer medication that belongs to the PARP (Poly ADP-ribose Polymerase) inhibitor class. It is used in the treatment of certain cancers, including prostate cancer and metastatic pancreatic cancer, by blocking PARP enzymes that cancer cells rely on to repair damaged DNA, ultimately slowing cancer growth and promoting cancer cell death. Depending on the patient's condition and treatment goals, Ribaxa 150mg Tablet may be prescribed alone or in combination with other anticancer therapies. Before starting treatment, patients should inform their healthcare provider about any history of liver, lung, heart, or kidney disorders, as these conditions may require additional monitoring during therapy. Regular blood tests may be recommended to assess blood cell counts and overall treatment safety. Ribaxa 150mg Tablet is not recommended during pregnancy or breastfeeding because it may cause harm to an unborn baby or nursing infant. Women of childbearing potential should undergo a pregnancy test before starting treatment and use effective contraception throughout therapy as advised by their doctor. Male patients should avoid donating sperm during treatment and for at least three months after the final dose. Regular medical follow-up and adherence to prescribed treatment are essential to ensure the safe and effective use of Ribaxa 150mg Tablet in managing advanced cancers and improving treatment outcomes.
Effective Cancer TherapyRibaxa+ 150mg Tablet utilizes Olaparib, a leading-edge anti-cancer agent, to target prostate cancer at the molecular level. This targeted approach inhibits cancer cell proliferation and supports improved patient outcomes. It is recommended for advanced stages where traditional therapies may fall short.
Safe Storage and HandlingTo retain its efficacy and safety, Ribaxa+ should be kept at room temperature between 20C and 25C. Proper storage preserves the tablet's stability and integrity until its expiration date in 2028. The packaging, containing 60 tablets per box, is designed for convenient handling.
FAQ's of Ribaxa+ 150mg Tablet:
Q: How should Ribaxa+ 150mg Tablet be taken for prostate cancer treatment?
A: Ribaxa+ 150mg Tablet is intended for oral use and should be taken exactly as prescribed by a healthcare professional, usually once or twice daily with or without food. Following your doctor's instructions ensures maximal effectiveness and safety in prostate cancer management.
Q: What is the active ingredient in Ribaxa+ 150mg Tablet and how does it work?
A: The tablet contains Olaparib, which targets and inhibits specific enzymes in cancer cells, impairing their ability to repair DNA and leading to cell death. This mechanism helps to control the progression of prostate cancer.
Q: When should Ribaxa+ 150mg Tablet be used during prostate cancer treatment?
A: Ribaxa+ is typically prescribed for patients with advanced prostate cancer, often after other treatments have not provided adequate results. Your healthcare provider will determine the appropriate timing and regimen based on your individual case.
Q: Where is Ribaxa+ 150mg Tablet manufactured and distributed from?
A: Ribaxa+ 150mg Tablet is manufactured in India and is distributed internationally by exporters, suppliers, and traders specializing in anti-cancer medications.
Q: What is the recommended process for storing Ribaxa+ 150mg Tablet?
A: To maintain quality, store Ribaxa+ at room temperature between 20C and 25C, away from excess heat, moisture, and direct sunlight. Always keep the medication in its original packaging until use.
Q: What are the key benefits of using Ribaxa+ 150mg Tablet?
A: The main benefit is its targeted action against cancer cells in advanced prostate cancer, offering improved disease control and a tailored treatment approach. Its efficacy and safety profile make it a valuable choice for eligible patients under medical supervision.